Lindis Bloodcare, a Hennigsdorf, Germany-based company developing a medical device to be used in oncology for the operation of tumours, raised over €5m in funding.
– High-Tech Gründerfonds (HTGF),
– Brandenburg Kapital,
– five private investors, as well as
– ILB grants from the “ProFIT” program of the European Regional Development Fund (totalling €3.3m).
The company intends to use the funds for the clinical development of its CATUVAB product.
Co-founded by Horst Lindhofer and Franzpeter Bracht, Lindis Bloodcare is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood collected during the operation. CATUVAB consists of a combination of an antibody and filter, thus enabling the reliable removal of tumor cells from the blood in the context of the standard ATS method.
The product and procedure can be integrated into everyday clinical practice and potentially become an integral part of a contemporary patient blood management process.